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Polymicrobial infections of the respiratory tract due to antibiotic resistant bacteria are a
great concern in patients with cystic fibrosis (CF). We therefore aimed at establishing
a functional metagenomic method to analyze the nasal resistome in infants with CF
within the first year of life. We included samples from patients before antibiotic treatment,
which allowed obtaining information regarding natural status of the resistome. In total,
we analyzed 130 nasal swabs from 26 infants with CF and screened for β-lactams
(ampicillin, amoxicillin-clavulanic acid, and cefuroxime) and other classes of antibiotic
resistances (tetracycline, chloramphenicol and trimethoprim-sulfamethoxazole). For 69
swabs (53% of total), we found at least one non-susceptible phenotype. Analyses of
the inserts recovered from non-susceptible clones by nanopore MinION sequencing
revealed a large reservoir of resistance genes including mobile elements within the
antibiotic naïve samples. Comparing the data of the resistome with the microbiota
composition showed that the bacterial phyla and operational taxonomic units (OTUs)
of the microbiota rather than the antibiotic treatment were associated with the
majority of non-susceptible phenotypes in the resistome. Future studies will reveal if
characterization of the resistome can help in clinical decision-making in patients with CF.
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INTRODUCTION
The respiratory tract microbiome is a complex ecosystem that evolves from birth to adulthood and
may be disordered during disease or antibiotic (AB) therapy (Bomar et al., 2017). Its composition is
influenced by many maternal and environmental factors, including birth mode and breast feeding
during the first months of life (Bogaert et al., 2011; Biesbroek et al., 2014a; Bosch et al., 2016).
Studies using 16S rRNA sequencing demonstrated that accelerated microbiota maturation was
associated with microbiota instability, a marker of susceptibility to respiratory tract infections
(RTI) (Biesbroek et al., 2014b; Bosch et al., 2017). In a previous study, we prospectively profiled
the nasal bacterial microbiota composition in infants with cystic fibrosis (CF) (Mika et al., 2016).
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Nasal swabs from infants with CF were collected every second
week during the first year of life (Mika et al., 2015). As patients
with CF suffer from frequent bacterial infections, the impact
of AB therapy early in life on the microbiota composition
was assessed (Mika et al., 2016; Prevaes et al., 2016). Analyses
showed a decrease in Staphylococcus aureus at and after antibiotic
treatment while coagulase-negative Staphylococci increased.
However, little is known about the antimicrobial susceptibility
profiles of the whole respiratory microbiota in CF. As patients
with CF are exposed to multiple courses of antibiotics, the
emergence and selection of AB resistant strains is an important
concern (Sherrard et al., 2014; Cuthbertson et al., 2016). In
the case of polymicrobial infections, β-lactamase-producing
bacteria may protect β-lactams-susceptible members of the
community by releasing these enzymes in the environment
and inactivating antimicrobial agents (Brook, 2004; Stiefel
et al., 2015). In addition, β-lactamases-positive Prevotella spp.
has been identified to be highly prevalent in patients with
CF and could passively protect the pathogen Pseudomonas
aeruginosa against the antimicrobial effects of ceftazidime
(Sherrard et al., 2016).
Culture-based methods for pathogen identification followed
by antimicrobial susceptibility testing are routinely performed
in clinical laboratories. However, a considerable amount of
commensal or potentially pathogenic bacteria of the microbiota
are not routinely screened for AB resistance (Grice and
Segre, 2011). Therefore, the antimicrobial susceptibility of the
entire bacterial community is often neglected and shotgun
metagenomics sequencing technologies have been recently used
for the detection of resistance genes within patients with
CF (Lim et al., 2014). Results from a very recent study
using shotgun metagenomics sequencing indicated that the
microbiome of CF patients with low pulmonary function is
enriched in genes encoding eﬄux-mediated antibiotic resistance
mechanisms (Bacci et al., 2017). However, it has been
acknowledged that the application of metagenomics sequencing
to large patient cohorts can be very expensive and that
combining metagenomic screening of pooled DNA extracts
with validatory quantitative PCR-based analyses may have the
potential to provide important insights into the resistome in
CF (Taylor et al., 2018). However, shotgun sequencing data
relies on databases which, even if well maintained, may not
reflect the entity of all resistance genes. In addition, it is
unclear if resistance genes derived by shotgun sequencing
express the actual resistance phenotype. In contrast, functional
metagenomics, which is also a culture-independent method,
enables the phenotypic identification of antimicrobial resistance
genes (ARG) in bacterial genomes, including those that are
currently unknown (Sommer et al., 2009; Mullany, 2014;
van der Helm et al., 2017).
In this study, we aimed at setting up and establishing a
functional metagenomic approach to describe the nasal resistome
in infants with CF during the first year of life. Furthermore,
we have aimed at more specifically investigating how the
composition of the resistome is associated with antibiotic
treatment and bacterial composition of the microbiota in
patients with CF.
MATERIALS AND METHODS
Samples, Study Design and Participants
During 2011–2014, nasals swabs were collected from infants
with CF enrolled in the prospective Swiss Cystic Fibrosis Infant
Lung Development (SCILD) cohort. The SCILD cohort includes
infants with CF diagnosed following new-born screening from
CF centers throughout Switzerland and was established in 2011
(Kieninger et al., 2017). Parents collected anterior nasal swabs
from 26 infants every second week during their first year of the
infant’s life (Mika et al., 2016; Korten et al., 2018). We selected all
samples with more than 40 ng/µL of PCR product after 16S rRNA
PCR and subsequent purification from our previous study (Mika
et al., 2016). We therefore analyzed 130 samples from 26 infants
using functional metagenomics. Detailed clinical information
regarding the patients was collected including age (months)
at swab collection and complete AB history (Supplementary
Table 1). The study was approved by the Ethics Committee of
the Canton of Bern, Switzerland. Written informed consent was
obtained from the parents of the participants in this study.
DNA Preparation and Functional
Metagenomic Assays
DNA was extracted from 200 µL of transport medium of
nasal swab using QIAamp DNA Mini Kit (Qiagen) following
provider’s instructions. To enrich our samples, whole genomic
DNA was amplified using a multiply-primed rolling circle
amplification approach (Dean et al., 2001): 10 U of ϕ29
polymerase (NEB, cat. No. M0269L) were used to amplify 5 µL
of extracted DNA with a final concentration of 50 µM random
primers (Promega, C1181) and 2mM dNTPs (Figure 1A). After
shearing with Megaruptor 2 (Diagenode), fragments between
2 and 9 kb were recovered, purified with AMPure XP beads
(Beckmann-Coulter) and end-repaired (NEB, E5060L, following
provider’s instructions) in reactions of 50 µL, with incubation
for 40 min at room temperature. After heat inactivation for
15 min at 70◦C, end-repaired DNA (2.5 µL, 20–100 ng/µL)
was ligated into pCR-Blunt (0.5 µL, 25 ng/µL) vector (Thermo
Fisher Scientific, K270040, following provider’s instructions, 5µL
reaction volume) for 5 h at 20◦C before heat inactivation at
70◦C for 20 min. We then transformed 2 × 25 µL NEB
10-beta electrocompetent E. coli (DH10B) cells with 2 × 2 µL
of the ligation product to create two cells libraries for each
sample (two libraries for reproducibility). Cells were grown
overnight in 10 mL LB medium supplemented with kanamycin
(50 µg/mL) for clones amplification (Figure 1A). We then
spread 150 µL of the libraries on agar plates containing
kanamycin and different classes of antibiotics at concentrations
that were inhibiting the wild-type strain [100 µg/mL ampicillin,
25 µg/mL cefuroxime, 40 µg/mL amoxicillin + 20 µg/mL
clavulanic acid, 10 µg/mL chloramphenicol (Cm), 23.75 µg/mL
sulfamethoxazole+ 1.25µg/mL trimethoprim (SXT), 600µg/mL
sulfamethoxazole and 10 µg/mL tetracycline] and incubated
for 24 h at 37◦C with 5% CO2. Similar concentrations for
ampicillin and tetracycline have been used previously (Luo
and Farrand, 1999). We aimed at using the same classes
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FIGURE 1 | Overview of the functional metagenomic approach, samples collection and patient history with antibiotic therapy. (A) Schematic representation of the
experimental workflow. (B) We used 130 nasal swabs from 26 infants with CF enrolled in a cohort study. We chose samples containing a decent amount bacterial
DNA (≥40 ng/µL 16S rRNA PCR product) for functional metagenomic analysis. Samples are represented according to patient antibiotic history at the time of
sampling; circles: antibiotic naïve, squares with red border: during an antibiotic treatment and squares: after one or more antibiotic therapy.
of antibiotics for functional metagenomics as used for the
treatment of the infants (Supplementary Table 1). Up to 50
clones non-susceptible against a specific antimicrobial agent
were picked, pooled in liquid LB supplemented with the
appropriate antibiotics and grown for 6 h at 37◦C (to obtain a
representative clone population). Plasmids were extracted using
(Promega, A1460, elution in 50 µL nuclease free water) from
1 mL of clones culture and inserts were amplified with M13
primers (Forward: 5′-GTAAAACGACGGCCAG-3′, Reverse: 5′-
CAGGAAACAGCTATGAC-3′, final concentration 0.2µM each)
using 0.2 U iProof polymerase (Bio-Rad, #1725301) with final
concentration of 200µM each dNTP for a total reaction of 25µL.
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PCR cycling protocol was: Denaturation for 2 min at 98◦C, 30
cycles of 30 s at 98◦C, 30 s at 51◦C for annealing, 5 min at
72◦C and a final amplification for 7 min in at 72◦C. We then
purified the PCR products (Promega, A9281, elution in 30 µL
Elution Buffer).
DNA Library Preparation and Nanopore
Sequencing
We used nanopore MinION sequencing from Oxford Nanopore
Technology (ONT) which is a technology currently under
development. We used the 96 PCR Barcoding Kit (ONT,
EXP-PBC096) and ligation sequencing kits for two directions
(2D) (SQK-NSK007) or 1D (SQK-LSK108) for flow cells version
R9 or R9.4 version to prepare the libraries, respectively. We
pooled purified PCR products in a way so that a specific
non-susceptible phenotype from a given sample was identified
by a unique barcode per sequencing run. Using 200 µL tubes,
22.5 µL of purified and pooled PCR products were end-repaired
and A-tailed using the Next Ultra II End Repair/dA-Tailing
Module (NEB, E7546L) following manufacturer’s instructions for
a final reaction volume of 30 µL and incubated for 30 min at
20◦C and then 30 min at 65◦C. End-repaired products were
purified using 15 µL of AMPure XP beads (Beckman Coulter
Inc., A63881) at room temperature for 5 min. Beads were
pelleted on a 96-wells magnet and washed twice with 150 µL
fresh 70% ethanol. DNA was eluted in 30 µL elution buffer
(EB; Qiagen) before ligation with 20 µL of Barcode Adapter
(ONT, EXP-PBC096), 10 µL Blunt/TA ligase Master mix (NEB,
M0367L), 9 µL 10x T4 buffer (NEB, B02020S) and nuclease free
water up to a final volume of 100µL. Enzyme was heat inactivated
at 70◦C for 15 min. We then performed the ‘barcoding’ PCR
(ONT, EXP-PBC096) including 5 µL of adapted DNA in a total
reaction volume of 50 µL. We verified the amplification of the
barcoded products by loading 2 µL of DNA before and after
PCR on a 1% agarose gel. Finally we pooled 8 µL of barcoded
PCR products from each sample and purified the DNA with
500µL AMPure XP beads and incubated at room temperature for
5 min with rotation. After having washed twice with 500 µL fresh
70% ethanol, the DNA library was eluted in 45 µL EB. Libraries
were prepared following manufacturer’s instructions (ONT,
SQK-NSK007 or SQK-LSK108) with the following increased
incubation times: 30 min at 20◦C and 30 min at 65◦C for the
end-repair/A-tailing reaction and 30 min for ligation. We loaded
the libraries following provider’s instructions on flow cells version
R9.0 or R9.4 for 2D or 1D sequencing, respectively.
Read Analysis
After 2D sequencing, we ran Metrichor1 (from ONT) for
basecalling with subsequent demultiplexing of the barcoded 2D
reads. Reads from 1D sequencing were basecalled and barcodes
demultiplexed using Albacore (1.0.4). In case less than 1000
reads were obtained for a specific barcode, we repeated the
sequencing of the corresponding inserts. We used poretools
(Loman and Quinlan, 2014) to convert fast5 to fastq files. For
each barcode, reads were assembled into contigs using Canu
1https://metrichor.com
(1.4) (Koren et al., 2017). In order to obtain contigs longer than
500 bp and keep the possible variety of inserts, we used the
following parameters for the assembly:−genomeSize = 0.022 m
(An estimate of the size of the genome; in our case it is
an estimate of the insert) −corMinCoverage = 5 (Limit read
correction to regions with at least this minimum coverage)
errorRate = 0.035 −contigFilter = “5 500 1.0 1.0 2” (min
number of reads assembled, minimum length of 500 bp, single
read span fraction of the contig, lower coverage span fraction,
lowest coverage depth). In the 45 cases (20.7%) where Canu
assembly failed because of a low number of reads, we increased
the parameter for estimated error rate to 0.045 and in case
of second failure (11 cases, 5%) we repeated the sequencing
of those inserts. Primers and vector sequences were removed
to obtain the final insert length. For 15 samples (6.7%), we
observed that two identical PCR products were ligated together
during the library preparation resulting in contigs containing
repetitive sequences. We identified genes conferring resistance
toward antibiotics according to the best hits obtained from
BLAST against NCBI nucleotide (nt) database (online tool,
December 2016–July 2017). The sequences were also compared
online with The Comprehensive Antibiotic Resistance Database
(CARD, July 2017, loose option) (Jia et al., 2017), Antibiotic
Resistance Genes database (ARDB) (Liu and Pop, 2009) and
ResFinder databases (Zankari et al., 2012). Sequences with less
than 85% identity over 90% of sequence to known antibiotic
resistance genes were classified as non-described, potentially
novel proteins.
Mobile Genetic Elements Detection and
Phyla Analysis
To investigate the presence of mobiles genetic elements
(MGE), we compared our sequences with the ICEberg
(Inserted and Conjugative elements) and ISFinder databases
(Sternberg, 1881; Bi et al., 2012). We also used RAIphy with
the “iterative refinement” option to predict the taxonomic
origin of our functionally selected DNA fragments (Pedersen
and Henrichsen, 1983). As previously described, this
composition-based classifier determines 7-mer profiles and
compares those profiles to those of RefSeq genomes to
accurately relate DNA fragments with a phylum source
(Forsberg et al., 2014).
Phylogenetic Tree of Amino Acid
Sequences
Predicted protein sequences were obtained using ORFfinder
(NCBI) (≥50 aa in length), aligned with MUSCLE
(software MEGA, 5.2.1) and approximately-maximum-
likelihood phylogenetic trees were built using FastTree2
(July 2017). The β-lactamases were categorized according
to Ambler classification (Bush and Jacoby, 2010). Predicted
protein sequences with less than 85% identity over 90%
of sequence to known β-lactamases were classified as
non-described proteins.
2http://www.microbesonline.org/fasttree
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Extended-Spectrum β-Lactamase (ESBL)
Screening
In addition, clones with an inserted class A or C β-lactamase
and non-described proteins were tested for extended-spectrum
β-lactamase (ESBL) phenotype using the double-disk synergism
test (DDST) on cation-adjusted Mueller-Hinton plates, with and
without cloxacillin (250 µg/mL) for the discrimination of AmpC
β-lactamases (Al Naiemi et al., 2009).
Protein Network
All identified genes coding for resistance proteins were listed
according to their non-susceptibility and grouped into the main
classes of antibiotics: β-lactamases (with Ambler classification),
dihydrofolate reductases (DHFR, folA or dfrG), thymidylate
synthase, ribosomal protection protein, acetyltransferase,
transporters and eﬄux pumps (ABC, MSF, or others) and
non-described proteins. A connectivity matrix was generated
with yEd Graph Editor (3.17.1) and a protein network built using
Cytoscape (3.5.1). Size of the nodes represented the frequency of
identification of a specific gene.
Statistical Analysis
Samples from infants were grouped as (1) AB-naïve (without
any AB history), (2) collected during an AB treatment, (3)
collected after a single AB treatment, or (4) collected after
more than one AB therapy. We then applied χ2 tests for
2 × 2 or 2 × 4 contingency tables to test the associations
of the tested antibiotics with AB treatment history of the CF
infants. Operational Taxonomic Units (OTU) for all samples
were obtained from a previous study on the exact same samples
(Mika et al., 2016). We calculated the beta-diversity using the
vegan package in R with the vegdist function (Oksanen, 2013)
using abundance- or binary-based Jaccard dissimilarity indices.
For these analyses, infants who only provided a single sample
for resistome analysis were excluded (n = 2). Plots illustrating
antimicrobial susceptibility or non-susceptibility were generated
using the metaMDS function with non-metric multidimensional
scaling (nMDS) as ordination method.
The sequence reads from functional resistome experiments
were submitted to the European Nucleotide Archive (accession
number: PRJEB24475).
Metagenomic Sequencing for Validation
To remove human reads from the metagenomic dataset, the
Illumina reads were mapped against the human genome
(GRCh38 with Decoy) using Bowtie 2 (Langmead and Salzberg,
2012) (Version 2.3.0). The fractions of human reads were
95.08, 97.64, and 85.62% for the samples CF1, CF2 and CF3,
respectively. The remaining non-human reads (SRA-Accession:
PRJEB30595) were mapped against the resistance gene databases
ResFinder (Zankari et al., 2012) and MEGARes (Lakin et al.,
2017) using Bowtie 2 (Langmead and Salzberg, 2012) (Version
2.3.0). All genes that were covered by at least one read
were identified and analyzed using SAMtools (Li et al., 2009)
(version 1.3).
RESULTS
Study Population and Description of
Non-susceptible Phenotypes Within
Nasal Swabs
We performed functional metagenomic analyses (Figure 1A)
of 130 nasal swabs from 26 infants with CF for this
FIGURE 2 | Network of all proteins identified conferring antitiotic resistance. We identified 171 resistance proteins and grouped them according to the main classes
of antibiotics observed: β-lactamases (with Ambler classification), dihydrofolate reductases (DHFR, folA or dfrG), thymidylate synthase, ribosomal protection protein,
acetyltransferase, transporters and efflux pumps (ABC, MSF or others) and non-described proteins. The respective non-susceptible phenotypes were recorded and
a network was built using Cytoscape (3.5.1). Each node represents a protein type identified and is connected to the antibiotics for which it presented
non-susceptibility. Size of the node represents the frequency of identification.
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study. The sample collection included 72 swabs (55.3%)
received during or following AB treatment (Figure 1B).
Patient characteristics are outlined in the online supplement
(Supplementary Table 1). We generated expression libraries
for all samples (n = 130), and resulting transformants were
then screened on solid agar media amended with a range
of different classes of antibiotics (Figure 1A). We aimed at
including the same classes of antibiotics as used for the
treatment of the infants with CF (Supplementary Table 1).
We obtained one or more non-susceptible phenotypes against
the tested AB for 68 (52.3%) samples [mean: 1 non-susceptible
phenotype, standard deviation (SD): 1.5]. Among all non-
susceptibilities, 52 (40%) and 41 (32%) samples were β-lactams-
non-susceptible and non-susceptible against folic acid synthesis
inhibitors, respectively. We also observed 10 (8%) and 13
(10%) samples being tetracycline- and chloramphenicol- (Cm)
non-susceptible, respectively.
Catalog of Antimicrobial Resistance
Genes (ARG) and Mobile Elements of
Functional Metagenomic Libraries
For subsequent Nanopore MinION sequencing, we barcoded
the libraries and then performed four sequencing runs using
2D (1 run) or 1D (3 runs) kits (Supplementary Tables 2–4
and Supplementary Figures 1–4). In total, we used up to 65
different barcodes per sequencing run (Supplementary Table 2)
and the total number of clones are illustrated in Supplementary
Tables 3, 4. We sequenced up to 50 clones per sample (i.e.,
50 colonies were picked for sequencing if ≥50 colonies were
counted, all colonies were picked if ≤ 50 colonies). Overall, we
obtained a mean of 16,004 reads for each barcode (n = 217).
We then used a total number of 65,394 good quality reads
for the subsequent assemblies (Supplementary Tables 2–4 and
Supplementary Figures 1–4). Average lengths of DNA inserts
Ambler classes 
Mobile elements 
IS elements - ICEberg 
FIGURE 3 | Phylogenetic tree of predicted β-lactamases identified. Predicted protein sequences were obtained using ORFfinder (NCBI) (≥50 amino acids in length)
using the genes received from functional metagenomics sequencing. β-lactamases (n = 64) were assigned to an Ambler class according the best hit from blast
against NCBI. Sequences with less than 85% identity over 90% of sequence to known β-lactamase were classified as non-described proteins. All sequences were
aligned with MUSCLE (software MEGA, 5.2.1) and an approximately-maximum-likelihood phylogenetic tree was built using FastTree
(http://www.microbesonline.org/fasttree/, July 2017).
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were 3.0 kb (SD: 1.4 kb, Supplementary Figures 5A,B). In
total, we assembled 213 contigs > 500 bp and identified 171
resistance genes.
For all tested ABs, we identified eﬄux systems as the
mechanism conferring resistance of which ABC and MSF
transporters were the most common (4.6 and 7.7% of
130 samples respectively) (Figure 2). The resistance genes
CmlA (chloramphenicol eﬄux pump) and MdfA (multidrug
transporter) were the most frequent proteins observed conferring
Cm-non-susceptibility. For tetracycline-non-susceptibility,
tet(K) was the most frequently identified protein (2.3%).
Dihydrofolate reductase (26.9%) and thymidylate synthase
enzymes (10.7%) were the most common proteins identified for
folic acid synthesis inhibitors (Figure 2).
Overall, β-lactams-non-susceptibility was most frequently
identified including 64 different predicted amino acid sequences
recovered coding for β-lactamases (Figure 3). We obtained
enzymes from all Ambler classes. We observed eight predicted
amino acid sequences with less than 85% identity over 90%
of sequence to any known β-lactamase and classified them as
non-described proteins. All non-described proteins conferred
non-susceptibility against all three β-lactams tested (ampicillin,
cefuroxime or amoxicillin-clavulanic acid). We also observed
ESBL phenotypes for eight recovered proteins (Figure 3 and
Table 1). Overall, mobile elements were discovered for 21 of 64
(32.9%) β-lactamases (Figure 3). The recovery of mobile elements
was independent of the lengths of the contigs (Supplementary
Figure 5A). However, a sequence length dependency was
received if only the β-lactamases were included (p < 0.05;
Supplementary Figure 5B). As for non-β-lactamases, MGE were
also received for some other genes, including tetM.
Accuracy of Annotation of Nanopore
Sequencing Reads
We also investigated how the error rate within reads
produced by Nanopore sequencing could affect the ARGs
detection and identification (annotation). We generated
mutant sequences from the original contigs with different
mutation rates (point mutations) and challenged them
against CARD database (Supplementary Material). The
presence of ARGs was detected in more than 90% of
the cases even with 3% of mutations introduced into the
sequences, with the exception of the sequences coding
for BRO-type β-lactamases (Supplementary Figure 6),
TABLE 1 | All proteins conferring β-lactam non-susceptibilities.
Non-susceptible phenotype
Ambler classes for β-lactamases NTotal Ampicillin Amoxicillin-clavulanic
acid
Cefuroxime ESBL-like
A AER-1 1 1 0 0
TEM-1-like 6 5 4 2 2
TEM-type 2 0 2 0
blaZ 12 12 0 0
BRO-type 7 6 0 4
CARB-type 2 2 1 0
CIA-type 3 1 0 3 2
Class A-type 2 1 1 0
B B1-MBL 5 4 2 2
EBR-1 B1-MBL 1 1 0 1
IND B1-MBL 1 1 1 1
L1- MBL 1 0 1 0
Metallo-dependent hydrolase 1 1 0 0
C ACT-type 1 0 1 0
AmpC 1 0 1 1
Class C-type 6 2 3 5 2
D OXA-213-like 1 1 1 0
OXA-286-like 2 0 2 0
OXA-type 2 1 2 0
Class D-type 1 1 0 0
Unknown non-described protein 6 1 2 3 2
Transporter/efflux pump NTotal Ampicillin Amoxicillin-clavulanic
acid
Cefuroxime ESBL
ABC transporter 6 0 1 5
MFS transporter 3 1 2 0
Other transporters 5 2 0 3
MBL, metallo-β-lactamases; ESBL, extended-spectrum β-lactamases.
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FIGURE 4 | Non-susceptible phenotypes were not associated with AB
treatment history. After functional metagenomics analysis of all samples
(n = 130), proportions of non-susceptible phenotypes observed for all AB
tested were calculated according to the AB status of the patient: (A) AB naïve
vs. non-naïve or (B) AB naïve (group 0), collected during an AB treatment
(group 1), collected after a single AB treatment (group 2), or collected after
more than one AB therapy (group 3). A χ2 test for a 2 × 2 or 2 × 4
contingency tables was applied for statistical significance. (A) Non-susceptible
phenotypes were more frequently recovered from patient with AB history.
(B) We observed an increasing trend for β-lactams resistance in patients who
received one or more AB therapies. Standard deviations are indicated.
for which the detection decreased rapidly with 1%
of mutations. The identification of β-lactamase gene
variant was affected by increasing mutation rates and
introducing point mutations of 3% introduced already a
misclassification of PDC-7 (AmpC-type, ESBL) in CMY-11
(class C β-lactamase).
Resistome Association With AB
Treatment and Bacterial (Microbiota)
Composition
We next investigated the association of the resistome with
the AB treatment of the CF patients (Figures 4A,B). There
were no significant differences in the proportions of non-
susceptible phenotypes between patients without an AB
history, during AB treatment or after therapy (Figures 4A,B).
However, we observed a non-significant trend for higher
β-lactams-non-susceptibility in infants with a history of one
or more AB therapies (Figure 4B). We then predicted the
possible taxonomic source (phylum) of each functionally
selected resistance contig by using RAIphy. Proteobacteria
and Firmicutes were the most prevalent predicted phyla
(Figure 5A), and β-lactamases showed the strongest, and
most predominant relationships with predicted bacterial
phyla. The β-lactamases from class A and B were enriched
within Proteobacteria, Firmicutes, and Bacteroidetes, but class
C and class D β-lactamases were exclusively predicted for
Proteobacteria (Figure 5B).
We also analyzed more closely if the β-lactams-non-
susceptibility was associated with significantly different
microbial community clusters derived from previously
received 16S rRNA gene data (Mika et al., 2016). Therefore,
we created nMDS plots based on the abundance and binary
based distance matrices of the operational taxonomic units
(97% sequence identity) and performed PERMANOVA
statistics with β-lactams-non-susceptibilities as factors.
There was a significant separation for both, abundance
(Figure 6A; P = 0.04) and binary-based analyses for
ampicillin (Figure 6B; P = 0.001). The differences were
less apparent but still significant for cefuroxime and
amoxicillin-clavulanic acid.
Comparing Functional Resistome With
Culture-Independent Shotgun
Metagenomics Sequencing
We then compared the outcomes of the functional resistome
with culture-independent shotgun metagenomics sequencing for
three samples. Based on our functional resistome approach, the
three samples showed several phenotypic resistances (Sample
ID CF1 was resistant for ampicillin, amoxicillin clavulanic acid,
cefuroxime sulfamethoxazole-trimethoprim, tetracycline and
chloramphenicol; Sample ID CF2 was resistant to cefuroxime and
Sample ID CF3 was resistant for sulfamethoxazole-trimethoprim,
chloramphenicol and tetracycline) for which 18, 1, and 5
resistance genes were found for CF1, CF2, and CF3 respectively.
The numbers of received sequences were 27,038,599 (for CF1),
32,276,677 (for CF2) and 36,395,636 (for CF3) and the sequence
coverages from the shotgun sequencing for the genes identified by
functional genomics are shown in Figure 7. We recovered reads
from culture-independent shotgun metagenomics sequencing for
18/18 (for ID Cf1), 0/1 (for ID CF2) and 5/5 (for ID CF3)
resistance genes. However, for two genes (2031.1 and 2031.4),
the read coverage was quite low. Certain resistance genes (e.g.,
2025.1, 2025.2 and 2025.3; all BRO-type Beta-Lactamases) were
found in multiple samples [indicated as CF1 (ID 2025), CF2
(ID 2026), and CF3 (ID 2031)]. Additional resistance genes
were identified using Resfinder for the shotgun metagenomics
reads (Supplementary Tables 5–7). This included hits for
antibiotics which were not (Lincosamide and Fosfomycin) or
could not be tested by the functional resistome approach
using E. coli as a host with kanamycine resistance plasmids
(macrolides and aminoglycosides). However, the read coverage
was generally low as compared to the opposite search as
outlined above.
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FIGURE 5 | Antimicrobial resistance genes (ARG) and the related phyla. We related all identified ARG (n = 171) to the closest bacterial phyla using RAIphy on the
contigs sequences obtained. Protein sequences were grouped according the main following families: β-lactamases (with Ambler classification), dihydrofolate
reductases, thymidylate synthase, ribosomal protection protein, acetyltransferase, transporters/efflux pumps (ABC, MSF or others) and non-described proteins. We
reveal the Proteobacteria, Firmicutes, Bacteroidetes, Actinobacteria, while other phyla are grouped into the “others.” (A) The majority of ARG came from
Proteobacteria and Firmicutes. (B) Classes A and B β-lactamases were related to Proteobacteria, Firmicutes or Bacteroidetes while class C and D were exclusively
related to Proteobacteria.
DISCUSSION
It has been postulated that CF patients have complex lung
microbiota within which there are many genetic exchanges
occurring by horizontal gene transfer. This promotes both, the
emergence and selection of multidrug-resistant bacteria that may
spread in this population and the evolution of the microbial
community that is specific to the disease (Rolain et al., 2011).
In this study, we analyzed the nasal resistome of infants with
CF during the first year of life using a functional metagenomics
protocol. We report that multiple antibiotic non-susceptibilities
including ESBLs are present within the first months of life
even if the infants have not yet been exposed to antibiotic
treatment. This indicates that antibiotic treatment may not play
a major role in the development of the resistome in the first
year of life. In addition, we show that microbiota composition
is associated with specific non-susceptible phenotypes. The latter
makes it challenging to differentiate between changes in the
carriage of resistance genes due do direct selective antibiotic
pressure versus changes in resistance genes carriage, because of
shifts in the relative abundance of the bacterial populations that
encode them which has already been noted in an earlier study
(Taylor et al., 2018).
The functional resistome approach enables detecting
antibiotic resistance phenotypes and resistances that have not
yet been described. This cannot be achieved by the shotgun
sequencing methods which have recently been used for the
investigation of the resistome in CF (Lim et al., 2014; Bacci
et al., 2017; Feigelman et al., 2017). However, as compared to
functional metagenomics, shotgun sequencing methods are
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FIGURE 6 | Beta-diversity analyses of all samples (n = 130) from infants with CF for ampicillin resistance using non-metric multidimensional scaling (nMDS).
Illustrated are (A) results for abundance based distance matrix (permutational multivariate ANOVA P = 0.04) and (B) binary based distance matrix (permutational
multivariate ANOVA P = 0.001). Ampicillin-non-susceptible samples were more similar to each other than compared with susceptible sample. Red; Sample is
ampicillin-non-susceptible. Black; Sample is susceptible toward ampicillin. Ordispider plots are illustrated which combine items to their centroid.
probably more sensitive because the used E. coli model may
present a poor system for the discovery of resistance genes
that originated from Gram-positive organisms (Crofts et al.,
2017). We therefore compared functional resistome analyses
with shotgun sequencing results for three samples. We indeed
revealed resistance genes for antibiotics (e.g., macrolides and
aminoglycosides) which were not detected by our functional
resistome approach. We hypothesize that both methods have
advantages and disadvantages and may be considered in the
future for resistome analyses in CF.
Using functional metagenomics, we generally detected
a large number of genes coding for β-lactam resistances of
which some of them were well known and their detection was
expected. This include the genes blaTEM−1 and blaBRO−type
which are very frequently present in Haemophilus influenzae
and Moraxella catarrhalis isolates, respectively (Farrell et al.,
2005; Hsu et al., 2012). Similarly, blaZ is often detected
in penicillin-non-susceptible Staphylococcus aureus and
coagulase-negative staphylococci (Olsen et al., 2006).
Interestingly, we found that the resistome also includes the
presence of some ESBLs, which are clinically relevant as they
could severely affect potential treatment outcomes. It was
recently speculated that the production of ESBL by commensal
bacteria of the CF respiratory microbiota might have a potential
indirect pathogenic role (Sherrard et al., 2016). However, even the
observation of some ESBLs in our study may be unsurprising as,
the blaCIA−type gene encodes an ESBL that has been found within
Chryseobacterium spp. (Matsumoto et al., 2012). Multidrug
resistance in Chryseobacteria has also been recently described
in a CF patient (Sharma et al., 2015). However we were able to
detect two ESBLs with mobile elements and a potentially new
ESBL, though we could not accurately trace the bacterial species,
as our chosen method is limited for this purpose.
We also investigated non-β-lactam-non-susceptibilities
in our study (Supplementary Table 1). Tetracycline-non-
susceptibilities were rare with tet(K) and tet(M) within
Firmicutes the most frequently detected ARGs. The tet(M)
gene has been described as being highly mobilizable and
includes the detection within Proteobacteria (Endimiani
et al., 2017). As for trimethoprim-sulfamethoxazole, selections
containing trimethoprim and D-Cycloserine predominantly
recovered dihydrofolate reductases, D-alanine-D-alanine
ligases, and thymidylate synthases, which are well-known
enzymes conferring resistance and have been frequently
described in other habitats (Forsberg et al., 2014). Finally
It has been shown that bacteria, such as Streptococcus
pneumoniae, can grow in medium supplemented with Cm
when non-susceptible bacteria expressing Cm acetyltransferase
(cat) are present, suggesting the relevance for functional
metagenomics investigation of the resistome for Cm
(Yurtsev et al., 2016).
Based on our results, we hypothesize that the infant nasal
microbiota and resistome does not yet reach final maturation
within the first year of life. A very recent study hypothesized, that
the majority of CF subjects older than four harbor a pathogen
dominated airway microbiome, compared to younger patients
with an oral-like airway microbiome (Muhlebach et al., 2018). As
for healthy children, it has been speculated that the maturation
of the microbiota composition is achieved after children reach
2 years of age (Stearns et al., 2015).
In our study, we used Nanopore MinION sequencing which
has some distinct advantages. Nanopore reads are longer
and typically capture the entire metagenomic inserts (van
der Helm et al., 2017), including sequences of MGE and/or
insertion sequences, which assures the definition and therefore
enable a better characterization of the “mobilizable” resistome.
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FIGURE 7 | Continued
FIGURE 7 | Continued
Comparison of the functional resistome with shotgun metagenomics
sequencing for three samples. Functional resistome analyses revealed 18
genes for sample ID CF1 (2025.1–2025.18), 1 gene for CF2 (2026.1) and 5
genes for CF3 (2031.1-2031.5). The plots illustrate the sequence coverage
from the shotgun sequencing for the genes identified by functional genomics.
We recovered reads from shotgun metagenomics sequencing for 18/18 (for ID
2025), 0/1 (for ID 2026), and 5/5 (for ID 2031) resistance genes. Certain
resistance genes (e.g., 2025.1, 2025.2, and 2025.3) were found in multiple
samples [indicated as CF1 (ID 2025), CF2 (ID 2026) and CF3 (ID 2031)].
In addition, the well-established barcoding protocols allow the
parallel processing of several samples and decrease considerably
sequencing cost. However, the error rates are still higher as
compared to other sequencing technologies (Loman et al., 2015;
Deschamps et al., 2016). This may be especially true in the case of
1D (as compared to earlier 2D) sequencing for which many raw
reads need to be received to ascertain some high quality contigs
after trimming and assembly (Loman et al., 2015). However, we
investigated how mutations or error rate could potentially impact
on the ARGs detection and found that the detection of ARGs was
robust even with a high proportion of mutations. Furthermore, as
Oxford Nanopore Technologies constantly make improvement
on the accuracy and throughput of nanopore reads, the results
obtained in this study are rather conservative and the approach is
expected to improve qualitatively with time.
There are major strengths in our study. We used a
functional metagenomics approach that directly targets antibiotic
non-susceptibly rather than providing overall and unspecific
genomic information. With this approach, well-known but also
new resistance mechanisms can be more directly identified.
Nanopore sequencing proved to be ideal for our study as the
technique produces long reads which facilitate the capture of the
entire metagenomic insert including, if present, mobile elements
(van der Helm et al., 2017). In addition, we have included a
large number of samples (n > 100) from a well-defined CF
cohort of infants during their first year of life (Mika et al.,
2016). For all samples, functional resistome and 16S rRNA
gene sequence data were available. Our study also had some
limitations. First, the sensitivity of functional metagenomics
is limited as nasal swabs have generally a low density of
bacteria and, therefore, whole functional resistome profiling is
not able to come up with an exhaustive description of the
antibiotic resistance gene repertoire. In addition, we had to
perform prior multiple displacement amplification which is
known to be error prone. We can also not guarantee that our
libraries are comprehensive as it was difficult to estimate the
library size which is normally a usual standard approach for
functional resistome projects (Moore et al., 2013). Also, some
resistance mechanisms may still remain undetected, such as
those related to distinct single nucleotide polymorphisms (SNPs)
within penicillin binding proteins of gram positive bacteria like
S. pneumoniae (Engel et al., 2014). We exclusively used the E. coli
model as we were primarily interested in the non-chromosomal,
plasmid-mediated resistance mechanisms (hence long read
sequencing), especially Beta-Lactamases. We indeed found
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two potential new ESBLs within mobile elements. However,
a standard operating procedure for functional metagenomics
using a gram positive bacterium rather than E. coli has to be
additionally established in the near future.
While the functional resistome has the potential to influence
clinical treatment, its implementation and relevance in the
treatment of patients with CF have to be more clearly investigated
in future studies using a larger group of children with CF. In
addition, we need more samples and information concerning the
‘healthy’ resistome of the upper (including the nose) and lower
respiratory tract.
CONCLUSION
We characterized the functional resistome of the nose in infants
with CF during the first year of life. We revealed the presence
of a large number or ARG, even if the infants were not yet
exposed to antibiotic treatment. Understanding the resistome
could potentially optimize clinical decision-making in patients
with CF but this needs to be further investigated in future studies
using clinically relevant samples.
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